Display options
Cite
Opoku-Acheampong AB, Penugonda K, Lindshield BL. Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth. Evid Based Complement Alternat Med. 2016;2016:8135135doi: 10.1155/2016/8135135.
Opoku-Acheampong, A. B., Penugonda, K., & Lindshield, B. L. (2016). Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth. Evidence-based complementary and alternative medicine : eCAM, 20168135135. https://doi.org/10.1155/2016/8135135
Opoku-Acheampong, Alexander B, et al. "Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth." Evidence-based complementary and alternative medicine : eCAM vol. 2016 (2016): 8135135. doi: https://doi.org/10.1155/2016/8135135
Opoku-Acheampong AB, Penugonda K, Lindshield BL. Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth. Evid Based Complement Alternat Med. 2016;2016:8135135. doi: 10.1155/2016/8135135. Epub 2016 May 04. PMID: 27272436; PMCID: PMC4870347.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2016;2016:8135135. doi: 10.1155/2016/8135135. Epub 2016 May 04.

Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth.

Evidence-based complementary and alternative medicine : eCAM

Alexander B Opoku-Acheampong, Kavitha Penugonda, Brian L Lindshield

Affiliations

  1. Department of Food, Nutrition, Dietetics and Health, Kansas State University, Manhattan, KS 66506, USA.

PMID: 27272436 PMCID: PMC4870347 DOI: 10.1155/2016/8135135

Abstract

Saw palmetto supplements (SPS) are commonly consumed by men with prostate cancer. We investigated whether SPS fatty acids and phytosterols concentrations determine their growth-inhibitory action in androgen-sensitive LNCaP cells and hamster flank organs. High long-chain fatty acids-low phytosterols (HLLP) SPS ≥ 750 nM with testosterone significantly increased and ≥500 nM with dihydrotestosterone significantly decreased LNCaP cell number. High long-chain fatty acids-high phytosterols (HLHP) SPS ≥ 500 nM with dihydrotestosterone and high medium-chain fatty acids-low phytosterols (HMLP) SPS ≥ 750 nM or with androgens significantly decreased LNCaP cell number (n = 3; p < 0.05). Five- to six-week-old, castrated male Syrian hamsters were randomized to control (n = 4), HLLP, HLHP, and HMLP SPS (n = 6) groups. Testosterone or dihydrotestosterone was applied topically daily for 21 days to the right flank organ; the left flank organ was treated with ethanol and served as the control. Thirty minutes later, SPS or ethanol was applied to each flank organ in treatment and control groups, respectively. SPS treatments caused a notable but nonsignificant reduction in the difference between left and right flank organ growth in testosterone-treated SPS groups compared to the control. The same level of inhibition was not seen in dihydrotestosterone-treated SPS groups (p < 0.05). Results may suggest that SPS inhibit 5α-reductase thereby preventing hamster flank organ growth.

References

  1. Lancet. 1995 Jun 17;345(8964):1529-32 - PubMed
  2. Arch Dermatol Res. 2001 Apr;293(4):200-5 - PubMed
  3. J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 - PubMed
  4. Phytomedicine. 1994 Sep;1(2):127-33 - PubMed
  5. Anal Bioanal Chem. 2008 Oct;392(3):427-38 - PubMed
  6. Cancer Res. 1991 Oct 1;51(19):5165-70 - PubMed
  7. J Steroid Biochem. 1984 Jan;20(1):515-9 - PubMed
  8. Nutr Cancer. 1998;32(1):8-12 - PubMed
  9. J Herb Pharmacother. 2005;5(1):17-26 - PubMed
  10. Am J Anat. 1950 Mar;86(2):191-233 - PubMed
  11. Prostate. 1996 May;28(5):300-6 - PubMed
  12. Mol Cell Biochem. 2003 Aug;250(1-2):21-6 - PubMed
  13. Prog Clin Biol Res. 1981;75A:1-24 - PubMed
  14. J Invest Dermatol. 1970 Jul;55(1):13-9 - PubMed
  15. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90 - PubMed
  16. J Steroid Biochem Mol Biol. 2002 Oct;82(2-3):233-9 - PubMed
  17. Cell Cycle. 2007 Mar 15;6(6):647-51 - PubMed
  18. Proc West Pharmacol Soc. 2003;46:153-5 - PubMed
  19. Biochem Biophys Res Commun. 2009 Feb 13;379(3):795-8 - PubMed
  20. Prostate. 2009 Dec 1;69(16):1724-9 - PubMed
  21. Nat Rev Cancer. 2001 Oct;1(1):34-45 - PubMed
  22. J Urol. 2000 Sep;164(3 Pt 1):876-81 - PubMed
  23. Cancer Res. 2009 Oct 15;69(20):8141-9 - PubMed
  24. JAMA. 2009 Jan 7;301(1):102-3 - PubMed
  25. J Invest Dermatol. 1997 Aug;109(2):152-7 - PubMed
  26. Pharmacol Res. 1996 Sep-Oct;34(3-4):171-9 - PubMed
  27. J Steroid Biochem. 1984 Jan;20(1):521-3 - PubMed
  28. Prostate. 1999 Sep 1;40(4):232-41 - PubMed
  29. Endocrinology. 1981 Feb;108(2):445-53 - PubMed
  30. Eur J Cancer Prev. 2001 Dec;10(6):507-13 - PubMed
  31. J Clin Endocrinol Metab. 1983 Jan;56(1):139-46 - PubMed
  32. Cancer Sci. 2008 Jan;99(1):81-6 - PubMed
  33. Cell Biol Int. 2001;25(11):1117-24 - PubMed
  34. Prostate. 2000 Apr 1;43(1):49-58 - PubMed
  35. Steroids. 1975 Aug;26(2):227-32 - PubMed
  36. PLoS One. 2012;7(1):e29068 - PubMed
  37. Biol Pharm Bull. 2009 Apr;32(4):646-50 - PubMed
  38. Nutrients. 2013 Sep 13;5(9):3617-33 - PubMed
  39. Biol Pharm Bull. 2002 May;25(5):622-6 - PubMed
  40. Anal Sci. 2009 Apr;25(4):553-7 - PubMed
  41. Prostate. 2007 May 1;67(6):661-73 - PubMed
  42. Endocr Relat Cancer. 2009 Jun;16(2):325-32 - PubMed

Publication Types